Novo Nordisk shares rise after Wegovy obesity pill launch
CNBC • • business
Key Points:
- Novo Nordisk's shares rose over 5% following early U.S. prescription data indicating a strong start for its new GLP-1 obesity pill, Wegovy, launched on Jan. 5.
- TD Cowen analysts described the launch as a "solid start" but emphasized the need for more data to confirm demand trends, noting that initial prescriptions may not include direct-to-consumer or telehealth channels.
- IQVIA and Symphony data suggest Wegovy prescriptions outpaced Eli Lilly’s Zepbound injectable during their respective first weeks, with around 3,100 to 4,290 prescriptions for Wegovy versus 1,300 to 1,900 for Zepbound.
- Analysts highlighted that Novo Nordisk
 { path { fill: %23EEEFE9 } })